Andere talen Cara Therapeutics, Inc.

Aandelen

CARA

US1407551092

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 29-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,7555 ^USD	+10,40%		+3,44%	+1,68%

22/03	Cara Therapeutics, Inc. kondigt het ontslag aan van Dr. Joana Goncalves als Chief Medical Officer, met ingang van 16 april 2024	CI
06/03	CARA THERAPEUTICS, INC. : Canaccord Genuity nog altijd een koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Cara Therapeutics, Inc. Announces Resignation of Dr. Joana Goncalves as Chief Medical Officer, Effective April 16, 2024	22/03
Cara Therapeutics to Host Notalgia Paresthetica Virtual KOL Event on Wednesday, March 27, 2024	08/03
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024	07/03
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024	07/03
Cara: Q4 Earnings Snapshot	04/03
Cara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	04/03
Earnings Flash (CARA) CARA THERAPEUTICS Reports Q4 Revenue $3M, vs. Street Est of $9.1M	04/03
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results	04/03
North American Morning Briefing : Stock Futures -2-	04/03
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024	12/02
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024	12/02
Cara Therapeutics to Cut Workforce Up to 50%, Halt Work on Chronic Kidney Disease; Chief Scientific Officer to Exit	22/01
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026	22/01
Cara Therapeutics, Inc. Prioritizes Late-Stage Notalgia Paresthetica Program	22/01
Cara Therapeutics, Inc. Announces Frédérique Menzaghi Departs as Chief Scientific Officer and SVP of Research & Development, Effective February 2, 2024	22/01
Top Midday Decliners	18/12
Cara Therapeutics, Inc. Announces Outcome from Dose- Finding Part A of the KIND 1 Study Evaluating Oral Difelikefalin for Mod Moderate-To-Severe Pruritus in Patients with Atopic Dermatitis	18/12
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis	18/12
Cara Therapeutics, Inc.(NasdaqGM:CARA) dropped from NASDAQ Biotechnology Index	15/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cara Therapeutics, Inc.

Aandelen

CARA

US1407551092

Andere talen

Filters